157 related articles for article (PubMed ID: 21512161)
1. Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target.
Straub A; Krajewski S; Hohmann JD; Westein E; Jia F; Bassler N; Selan C; Kurz J; Wendel HP; Dezfouli S; Yuan Y; Nandurkar H; Jackson S; Hickey MJ; Peter K
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1607-16. PubMed ID: 21512161
[TBL] [Abstract][Full Text] [Related]
2. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.
Patil SB; Jackman LE; Francis SE; Judge HM; Nylander S; Storey RF
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2385-91. PubMed ID: 21071697
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous Platelet P2Y12 and P2Y1 ADP Receptor Blockade: Are Two Better Than One?
Vaduganathan M; Bhatt DL
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):427-8. PubMed ID: 26912743
[No Abstract] [Full Text] [Related]
6. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
[TBL] [Abstract][Full Text] [Related]
7. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
8. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
9. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides.
Delierneux C; Donis N; Servais L; Wéra O; Lecut C; Vandereyken M; Musumeci L; Rahmouni S; Schneider J; Eble JA; Lancellotti P; Oury C
J Thromb Haemost; 2017 May; 15(5):983-997. PubMed ID: 28296036
[TBL] [Abstract][Full Text] [Related]
10. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor to prevent restenosis: new drug for an old hypothesis?
Cayla G; Montalescot G; Collet JP
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2320-2. PubMed ID: 21084699
[No Abstract] [Full Text] [Related]
12. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
13. Effects of ticlopidine on von Willebrand factor-mediated shear-induced platelet activation and aggregation.
Goto S; Tamura N; Sakakibara M; Ikeda Y; Handa S
Platelets; 2001 Nov; 12(7):406-14. PubMed ID: 11674857
[TBL] [Abstract][Full Text] [Related]
14. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries.
Andre P; Delaney SM; LaRocca T; Vincent D; DeGuzman F; Jurek M; Koller B; Phillips DR; Conley PB
J Clin Invest; 2003 Aug; 112(3):398-406. PubMed ID: 12897207
[TBL] [Abstract][Full Text] [Related]
15. New P2Y₁₂ inhibitors.
Storey RF
Heart; 2011 Aug; 97(15):1262-7. PubMed ID: 21742618
[No Abstract] [Full Text] [Related]
16. P2Y
Hensch NR; Karim ZA; Pineda J; Mercado N; Alshbool FZ; Khasawneh FT
Biochem Biophys Res Commun; 2017 Nov; 493(2):1069-1074. PubMed ID: 28928091
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism.
Oestreich JH; Ferraris SP; Steinhubl SR; Akers WS
Thromb Res; 2013 Feb; 131(2):e64-70. PubMed ID: 23245937
[TBL] [Abstract][Full Text] [Related]
18. Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12.
Zhang Y; Ye J; Hu L; Zhang S; Zhang SH; Li Y; Kunapuli SP; Ding Z
J Thromb Haemost; 2012 Oct; 10(10):2149-57. PubMed ID: 22906019
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of platelet functional changes and effects of anti-platelet agents on in vivo hemostasis under different gravity conditions.
Li S; Shi Q; Liu G; Zhang W; Wang Z; Wang Y; Dai K
J Appl Physiol (1985); 2010 May; 108(5):1241-9. PubMed ID: 20133435
[TBL] [Abstract][Full Text] [Related]
20. P2 receptors, platelet function and pharmacological implications.
Gachet C
Thromb Haemost; 2008 Mar; 99(3):466-72. PubMed ID: 18327393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
